Cis-diamminedichloroplatinum(II) (CDDP) is considered as one of the most effective antitumor agents for ovarian carcinoma. CDDP-based chemotherapy has clearly improved the response rate in the treatment of ovarian carcinoma, but its clinical potential is often counteracted by intrinsic or acquired resistance and its impact on survival has been only marginal in most cases. Effective chemotherapy for ovarian carcinoma with such CDDP resistance is still not established. Thus, development of antitumor drugs which can be substituted for CDDP is of great importance.
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Ginseng is one of the most widely used natural tonics in Oriental countries. Odashima et al. 1, 2) have reported that a crude fraction of ginsenosides extracted from roots of Panax ginseng CA Meyer induced a phenotypic reverse transformation in cultured Morris hepatoma cells. Ginsenoside Rh 2 (Rh 2 ) is a plant glycoside with a dammarane skeleton, resembling a steroid skeleton, as an aglycone; it has one sugar at C-3 and the capacity to inhibit the growth of and to stimulate melanogenesis in B16 melanoma cells. Recently, we have also demonstrated that i.p. and p.o. administration of Rh 2 inhibited the tumor growth of human ovarian cancer cells inoculated into nude mice and also had an adjuvant effect with CDDP. 3, 4) In addition, it has been reported that the long-term p.o. administration of red ginseng augmented natural killer (NK) activity not only in mouse, but also in human. 5, 6) The present study extends our previous in vitro and in vivo observations. We now report that p.o. administration of Rh 2 is superior to i.p. administration with regard to antitumor activity and has an apoptosis-inducing effect in addition to an augmenting effect on NK activity.
MATERIALS AND METHODS
Agents Rh 2 was kindly supplied by the Korean Tobacco and Ginseng Co., Korea and Seikanshou Co., Japan. The molecular mass and purity of the Rh 2 were 618 Da and more than 99.9%, respectively. Rh 2 was dissolved in absolute ethanol and stored at 4°C CDDP was obtained from Bristol-Myers Squibb Co., Ltd. (Tokyo). These drugs were diluted with medium or saline to the desired concentrations prior to use. Cell lines HRA cell line was established from ascites of a patient with serous cystadenocarcinoma of the ovary.
7)
The KK cells were established from ascites of a patient with clear cell carcinoma of the ovary who did not respond to CDDP-based combination chemotherapy.
8) KF cells were established from tissue of a patient with serous cystadenocarcinoma of the ovary.
9) CDDP-resistant KFr cells were obtained by repeated exposure of the KF cells to escalating doses of CDDP. 10) These cell lines were incubated in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, 100 units penicillin/ml and 100 µg streptomycin/ml (GIBCO, Grand Island, NY) in 5% CO 2 at 37°C. The medium was changed every 3 days, and the cells were passaged when they reached confluence. In vitro treatment To determine the concentrations of CDDP and Rh 2 required for 50% inhibition (IC 50 ) of HRA, KK, KF and KFr cell proliferations in vitro, we seeded 5×10 2 cells for HRA, KF and KFr and 2×10 3 cells for KK in 96-well flat-bottomed microtest-plates (Becton Dickinson Labware, Franklin Lakes, NJ) and incubated them in the absence or presence of CDDP and Rh 2 in a humidified atmosphere of 5% CO 2 at 37°C. After incubation for 5 days, cell viability in each well was measured using a crystal violet staining method. 11) Briefly, an equal volume of 10% formalin phosphate-buffered saline containing 0.2% crystal violet was added to each well and left in room temperature for 20 min. The plates were washed twice with distilled water and dried in room temperature, then the absorbance at 590 nm of stained cells was measured by an automatic microtest-plate reader (Multiscan MCC/340, Titertek, Flow Laboratories Inc., VA). Average absorbance of the control wells in the absence of drugs was regarded as 100%, and the percentage cell growth in each well was calculated. IC 50 values of CDDP and Rh 2 were calculated from graphical plots. Flow cytometry Cell cycle phase distribution analysis was performed with a FACSCalibur TM flow cytometer (Nippon Becton Dickinson Co., Ltd., Tokyo) using propidium iodide-stained nuclei of the cells.
12)
DNA fragmentation DNA was analyzed by a gel electrophoresis method as described previously. 13) In this method, DNA fragments of apoptotic cells appear as multimers of 200 bp.
Morphological identification of apoptotic cells
To facilitate identification and quantification of apoptotic cells in formalin-fixed, paraffin-embedded sections, we employed a staining method that was developed for tissue sections. 14) This method involves in situ nick end labeling (TUNEL) of DNA strand breaks by the incorporation of biotinylated nucleotides with polymerase. It enabled recognition of apoptotic cells by the combination of the TUNEL signals and the morphologic features. For all stainings, slides were counterstained with 1% methyl green. The apoptotic signal was identified by conventional light microscopic examination. Nude mice Female BALB/c nude mice (about 6 weeks old) were obtained from Japan Clea Laboratories, Tokyo, Japan, and maintained in a pathogen-free environment. The animals were inspected daily and tumor growth was determined by measurement of diameters of the tumor nodule in two dimensions with a caliper. Tumor volume (cm 3 ) was calculated by use of the following equation; 4/3×π[(r 1 +r 2 )/2] 3 where r 1 is longitudinal radius and r 2 is transverse radius. When necessary, the animals were killed and dissected. The tumor tissues were fixed in formalin for histological examination. Large tumors (more than 2 cm in diameter) contained a wide necrotic area in the center. Distant metastases were not observed during the experimental period. Unless treated, all mice died of tumor burden within 100 days after tumor inoculation. In vivo treatment KK cells were not heterotransplantable to nude mice. Transplantability of KFr cells to nude mice was unstable showing a 40-70% success rate. Although both HRA and KF cells showed 100% transplantability, HRA cells were exclusively used for the in vivo experiments because the inhibitory effect of Rh 2 on the in vitro proliferation of HRA cells was greater than that of KF cells (Table I ). When 10 6 HRA cells were inoculated s.c. into the right flank of nude mice, all mice formed a tumor within 14 days. The first experiment was performed to determine the effect of weekly or daily p.o. administration of Rh 2 and its combined effects with CDDP. Treatment 3 form an ulcer with a large necrotic area in the center, the tumor size measured in the surviving mice could not be determined exactly. Therefore, the tumor-growth curve was presented until 42 or 49 days after tumor inoculation (Figs. 4 and 5) . NK activity Spleen cells obtained on 7, 14, 21 and 28 days after HRA cell inoculation were used as effector cells against YAC-1 cells. Significant 51 Cr-release was observed at 4 h; however, maximum lysis was seen at 18 h. Therefore, for comparative purposes, the longer assay was exclusively used. Target cells were labeled with 100 µCi of 51 Cr (New England Nuclear, Boston, MA) for 1 h at 37°C. The 51 Cr-release assay was performed at the effector:target ratio of 100:1, 50:1 or 25:1. Cytotoxicity was determined in terms of the amount of 51 Cr (cpm) released from target cells, according to the following formula: Specific lysis (%) = (test release − spontaneous release) / (maximum release − spontaneous release) × 100. Spontaneous and maximum releases were from target cells incubated in medium and in medium to which 1 N HCl had been added, respectively. Statistical analysis The significance of differences in survival times among groups was determined by the Mann-Whitney U test. Contingency-table analysis and the χ 2 test were used for comparison of effects of treatment on the tumor growth. NK activity against YAC-1 cells was analyzed using Student's t test.
RESULTS
Effects of CDDP and Rh 2 on human ovarian cancer cell proliferation in vitro As shown in Table I , HRA cells had the highest sensitivity to CDDP and Rh 2 among (Fig. 1) . Effects of Rh 2 on apoptosis of HRA cells in vitro and in vivo Rh 2 induced apoptosis of HRA cells around the IC 50 dose in vitro (Fig. 2) . To determine the effects of Rh 2 on apoptosis of HRA cells in vivo, i.p. or p.o. administration of Rh 2 to nude mice with an approximately 1 cm diameter tumor was performed after HRA cell inoculation. At 7 days after i.p. or p.o. treatment with 0.4 mg/kg of Rh 2 , the tumor was stained as described in "Materials and Methods." P.o. treatment with Rh 2 induced significantly more apoptotic cells in the tumors than did i.p. treatment (Fig. 3) . Effects of Rh 2 on tumor growth and survival of nude mice with HRA cell tumor To evaluate the in vivo effects of Rh 2 on the tumor growth and survival of the tumor-bearing mice, we performed two experiments using nude mice. First, to examine the effect of p.o. treatment with Rh 2 , weekly or daily administration was compared. P.o. and weekly (but not daily) administration of 0.13 and (Fig. 4A) . P.o. and daily treatment with 0.4 mg/kg Rh 2 and its combination with CDDP resulted in a significant prolongation of the survival time (P<0.05), compared to treatment with CDDP alone (Fig. 4B) . Next, we examined whether p.o. and daily administration of Rh 2 has a dose-dependent inhibitory effect on the tumor growth. When mice were treated with 4 mg/kg CDDP, the tumor growth was markedly inhibited while about a half of the mice died as a result of loss of body weight. On the other hand, p.o. and daily treatment with 0.4 mg/kg Rh 2 had an inhibitory effect on the tumor growth comparable to that of 4 mg/kg CDDP, without any adverse side-effect such as weight loss or lowering of hematocrit (Fig. 5) , consequently resulting in a significant increase of life span (ILS) ( Table II) . However, the tumor-inhibitory effect was not enhanced at higher doses (0.8 and 1.6 mg/kg) of Rh 2 . Effects of Rh 2 on the NK activity of spleen cells in tumor-bearing nude mice We measured the NK activity of spleen cells obtained from untreated, 2 mg/kg CDDP alone-, and 0.4 mg/kg Rh 2 alone-treated nude mice. Spleen cells from untreated nude mice showed a significant increase in the NK activity (P<0.05) at 21 and 28 days after tumor inoculation, compared to that of intact nude mice. Treatment with CDDP alone hardly affected the NK activity. In contrast, p.o. and daily administration of Rh 2 resulted in a significant (P<0.05) increase in the NK activity, compared to treatment with CDDP alone (Table III) .
DISCUSSION
In the present study, we confirmed that Rh 2 inhibited proliferation of not only HRA cell line, but also other human ovarian cancer cell lines (Table I) . Although the precise mode of action of Rh 2 is still unclear, it has been reported that Rh 2 not only arrests the cell cycle of B16 melanoma cells at the G 1 /G 0 phase, but also stimulates melanogenesis in these cells. 15, 16) Flow-cytometric analysis revealed that when HRA cells were incubated with 0.15 µM CDDP or 30 µM Rh 2 for 3 days, CDDP blocked the cell cycle in the G 2 -M phase, while Rh 2 caused G 1 -arrest with induction of apoptosis (Fig. 1) . In addition, Rh 2 seemed to increase the cell adhesiveness to a plastic surface and the cell agglutinability (data not shown), in accordance with previous observations. 16) As shown in Fig. 2 , Rh 2 induced apoptosis in HRA cells more easily at around the IC 50 dose than did CDDP. Apoptosis is a late event in cell death, resulting from a number of distinct pathways.
17) The pathway which is involved in induction of apoptosis by Rh 2 should be addressed. We have previously demonstrated that i.p. administration of Rh 2 had an adjuvant effect to CDDP and improved the survival rate of tumor-bearing nude mice. 4) Red ginseng containing Rh 2 has been used as a preventive medical agent for more than 2000 years in Asian countries, especially in Korea, Japan and China. The effect of i.p. pretreatment with Rh 2 on the tumor growth was examined to test whether it can be effective for cancer treatment. I.p. administration of Rh 2 alone did not cause any significant inhibition on the tumor growth. Even if Rh 2 was injected i.p. before tumor inoculation, no inhibitory effect was observed. Only when Rh 2 was combined with CDDP, a growth-inhibitory effect on the tumor growth was observed (P<0.05, compared to untreated, CDDP alone-and Rh 2 alone-treated groups). 3) These results suggest that i.p. administration of Rh 2 is ineffective.
Thus, in the first experiment we investigated the effect of p.o. administration of Rh 2 on tumor growth and survival (Fig. 4) . When Rh 2 alone was administered p.o. once a week, no inhibitory effect on the tumor growth was observed (Fig. 4A) . However, daily p.o. administration of 0.4 mg/kg Rh 2 resulted in a significant (P<0.01) tumor growth retardation, showing a greater antitumor activity than weekly i.p. administration of 2 mg/kg CDDP. Moreover, the survival time was significantly (P<0.05) prolonged and 5 out of 10 nude mice survived during the experimental period (Fig. 4B) . Next, we determined whether daily p.o. administration of Rh 2 shows a dosedependent effect on the tumor growth (Fig. 5) . Although Rh 2 did not show a dose-dependent inhibitory effect between 0.4 mg/kg and 1.6 mg/kg, the degree of inhibition by these doses of Rh 2 was significantly (P<0.05) higher than that by 2 mg/kg CDDP. In the previous study, we found that 0.02 mg/kg Rh 2 showed significantly less inhibitory effect on the tumor growth than 0.3 mg/kg Rh 2 .
4) Thus, 0.4 mg/kg Rh 2 seemed to be an effective and optimal dose with regard to inhibition of the tumor growth. When 4 mg/kg CDDP was administered i.p. once a week, the strongest tumor growth inhibition was obtained. However, 5 out of 10 mice treated with this dose died owing to loss of body weight and a rapid fall of hematocrit during the treatment course (data not shown). In this case, prolongation of the survival time could not be obtained (Table II) . On the other hand, a high dose of Rh 2 (1.6 mg/kg) administered p.o. daily had no adverse effect. The precise mode of action of Rh 2 is still unknown. Previously, we suggested that NK activity was modulated by Rh 2 .
18) Therefore, we examined the time course of NK activity in the spleen cells from nude mice treated with Rh 2 . Although spleen cells from intact nude mice showed very weak NK activity, those from tumor-bearing nude mice at Day 21 and 28 showed a significant increase in the NK activity. Treatment with 2 mg/kg CDDP alone hardly affected the NK activity, while daily p.o. administration of 0.4 mg/kg Rh 2 alone remarkably augmented the NK activity (Table II) , suggesting the relevance of Rh 2 to the enhancement of the NK activity. In addition to enhancement of NK activity by Rh 2 , p.o. administration of Rh 2 induced a higher degree of apoptosis in the tumor than did i.p. administration (Fig. 3) , and consequently when Rh 2 was administered p.o., but not i.p., the tumor growth was markedly inhibited. It is well-known that protopanaxadiol (PPD), an aglycone formed from Rh 2 as a result of intracellular deglycosylation, inhibits the cell growth more strongly than Rh 2 itself. Therefore, the marked inhibition of the tumor growth by p.o. administration of Rh 2 may be attributable to more efficient conversion of Rh 2 to PPD in the case of p.o. administration compared to i.p. administration. The Rh 2 and PPD contents in the tumor should be examined.
In conclusion, we have demonstrated that p.o., but not i.p., administration of Rh 2 shows a potent antitumor effect comparable or even superior to i.p. administration of CDDP, and can be safely done without adverse sideeffects. Considering the toxicity of CDDP, the use of Rh 2 alone would seem to warrant further clinical evaluation.
